PPTD.F Stock Overview
PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
PeptiDream Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥9.50 |
| 52 Week High | JP¥12.40 |
| 52 Week Low | JP¥7.40 |
| Beta | 0.75 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -78.51% |
| 5 Year Change | -81.73% |
| Change since IPO | -90.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| PPTD.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 0.1% | 2.2% |
| 1Y | n/a | -1.0% | 22.8% |
Return vs Industry: Insufficient data to determine how PPTD.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how PPTD.F performed against the US Market.
Price Volatility
| PPTD.F volatility | |
|---|---|
| PPTD.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PPTD.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PPTD.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 603 | Patrick Crawford Reid | www.peptidream.com |
PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform that enables the production of non-standard peptide libraries for the identification of potent and selective macrocyclic peptide candidates, which then can be developed into peptide-based, small molecule-based, peptide-drug conjugate, and multi-functional peptide conjugates -based therapeutics and diagnostics. Its development pipeline include PD-L1 indicated for oncology and currently under Ph1 clinical phase development stage; PD-L1 BMS-986229 indicated for oncology and currently under Ph1 clinical phase development stage; CD38 BHV-1100 + NK Cells indicated for multiple myeloma and currently under Ph1 clinical phase development stage; S2-protein PA-001 indicated for COVID-19 and currently under Ph1 clinical phase development stage; GhR AZP-3813 indicated for acromegaly/NET and currently under Ph1 clinical phase development stage; Glypican-3 indicated for liver cancer and currently under preclinical development stage; Myostatin indicated for DMD/muscle disorders and currently under preclinical development stage; TfR indicated for neuromuscular disorders and currently under preclinical development stage; c-Kit indicated for allergic condition and currently under preclinical development stage; c-Met currently under preclinical development stage; and HA-protein indicated for influenza and currently under preclinical development stage.
PeptiDream Inc. Fundamentals Summary
| PPTD.F fundamental statistics | |
|---|---|
| Market cap | US$1.35b |
| Earnings (TTM) | US$19.45m |
| Revenue (TTM) | US$184.01m |
69.3x
P/E Ratio7.3x
P/S RatioIs PPTD.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PPTD.F income statement (TTM) | |
|---|---|
| Revenue | JP¥28.71b |
| Cost of Revenue | JP¥11.49b |
| Gross Profit | JP¥17.22b |
| Other Expenses | JP¥14.18b |
| Earnings | JP¥3.04b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
| Earnings per share (EPS) | 23.42 |
| Gross Margin | 59.97% |
| Net Profit Margin | 10.57% |
| Debt/Equity Ratio | 55.1% |
How did PPTD.F perform over the long term?
See historical performance and comparison